|
CEP72 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.23990000489016E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.87549999869563E-08 |
| Normal-vs-Stage2 |
1.620870E-04 |
| Normal-vs-Stage3 |
1.02629999998438E-06 |
| Normal-vs-Stage4 |
2.31160000030428E-07 |
| Stage1-vs-Stage2 |
9.033600E-01 |
| Stage1-vs-Stage3 |
8.897000E-01 |
| Stage1-vs-Stage4 |
4.757000E-01 |
| Stage2-vs-Stage3 |
9.855600E-01 |
| Stage2-vs-Stage4 |
6.783400E-01 |
| Stage3-vs-Stage4 |
5.554400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.14369999529396E-08 |
| Normal-vs-AfricanAmerican |
7.035500E-03 |
| Normal-vs-Asian |
9.84869999998139E-07 |
| Caucasian-vs-AfricanAmerican |
4.785800E-01 |
| Caucasian-vs-Asian |
6.929400E-01 |
| AfricanAmerican-vs-Asian |
4.286200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.35059999999354E-05 |
| Normal-vs-Female |
1.38480005240638E-09 |
| Male-vs-Female |
1.995230E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.7044000039389E-08 |
| Normal-vs-Age(41-60Yrs) |
3.28159999951616E-07 |
| Normal-vs-Age(61-80Yrs) |
2.21579999999388E-05 |
| Normal-vs-Age(81-100Yrs) |
4.716000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.886400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.377400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.818000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.353600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.441400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.504800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.087800E-02 |
| Classical-VS-Follicular |
2.339600E-01 |
| Classical-VS-Other |
9.014000E-01 |
| Classical-VS-Normal |
5.38600000155043E-08 |
| Tall-VS-Follicular |
7.309800E-01 |
| Tall-VS-Other |
6.114800E-01 |
| Tall-VS-Normal |
1.07259999992948E-07 |
| Follicular-VS-Other |
6.121000E-01 |
| Follicular-VS-Normal |
1.27859999998758E-06 |
| Other-VS-Normal |
2.813200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.27010000189532E-08 |
| Normal-vs-N1 |
1.1809000444174E-09 |
| N0-vs-N1 |
7.676300E-02 |
|
|
